Tomasz Kluz
Overview
Explore the profile of Tomasz Kluz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wrobel J, Zapala L, Niemczyk G, Poleszak E, Dobrowolski P, Kluz T, et al.
Biomolecules
. 2025 Feb;
15(2).
PMID: 40001493
We aimed to determine whether berbamine (BBM) would have an effect on retinyl acetate (RA)-induced cystometric and biochemical parameters, characteristic of bladder overactivity. BBM exhibits anti-inflammatory, anti-oxidant, and muscle-relaxant effects...
2.
Kuzmycz O, Kowalczyk A, Bolanowska A, Drozdzowska A, Lach J, Wierzbinska W, et al.
Front Cell Infect Microbiol
. 2025 Feb;
15:1511625.
PMID: 39958933
Introduction: Endometrial cancer (EC) is a significant gynecological malignancy with increasing incidence worldwide. Emerging evidence highlights the role of the uterine microbiome in the pathogenesis of EC. This study aims...
3.
Misiek M, Witczak G, Picheta A, Skuza M, Misiek A, Kluz T, et al.
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860572
Endometrial cancer is becoming an even more significant health concern in Poland, with incidence and mortality rates rising each year. : This retrospective study analyzed 1532 patients surgically treated for...
4.
Szatkowski W, Kluz T, Cieslak-Stec M, Sliwinska M, Nowak-Jastrzab M, Winkler I, et al.
Cancers (Basel)
. 2025 Jan;
17(2.
PMID: 39857995
Endometrial cancer (EC) incidence and mortality have been steadily rising globally over recent decades. The introduction of advanced molecular technologies, such as next-generation sequencing (NGS) alongside the FIGO 2023 classification,...
5.
Wrobel J, Iwaniak P, Dobrowolski P, Chwil M, Sadok I, Kluz T, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684342
Despite the close and clinically confirmed association between depression and overactive bladder, it remains unclear whether this affective disorder is a factor causing overactive bladder or whether overactive bladder is...
6.
Misiek M, Picheta A, Michalczyk K, Kluz T, Wrobel A, Stojko R, et al.
Ginekol Pol
. 2024 Nov;
PMID: 39611468
The FIGO staging system is an integral part of the therapeutic and treatment process in female genital tumors. It cements the knowledge gained to date to plan patient treatment prognosis...
7.
Kluz-Barlowska M, Kluz T, Paja W, Sarzynski J, Barnas E, Laczynska-Madera M, et al.
Sci Rep
. 2024 Oct;
14(1):24923.
PMID: 39438723
Patients with high-grade ovarian cancer have a poor prognosis, thus effective treatment remains an unmet medical issue of high importance. Moreover, finding the reason for resistance to cisplatin is a...
8.
Serefko A, Wrobel J, Szopa A, Dobrowolski P, Kluz T, Wdowiak A, et al.
Neurourol Urodyn
. 2024 Oct;
44(1):229-244.
PMID: 39402852
Aim: In the present study, we wanted to check whether TCS OX2 29 (TCS), a potent selective antagonist of OX2 receptors, would have positive effects in an animal model of...
9.
Zuzak T, Bogaczyk A, Krata A, Kaminski R, Paneth P, Kluz T
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335141
Objectives: The metabolic pathway of cancerous tissue differs from healthy tissue, leading to the unique isotopic composition of stable isotopes at their natural abundance. We have studied if these changes...
10.
Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al.
Hered Cancer Clin Pract
. 2024 Sep;
22(1):19.
PMID: 39300540
Objective: To investigate whether Molybdenum blood level is a marker of cancer risk on BRCA1 carriers. Methods: A prospective cohort study was conducted among 989 initially unaffected women with a...